Heart Defects, Congenital
0
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
XeltisNetherlands - Eindhoven
3 programsVascular Graft, Model COR-VG-001N/A1 trial
Xeltis Pulmonary Valved ConduitN/A1 trial
Xeltis Vascular Patch, Model COR-VP-001N/A
Active Trials
QT
Q TherapeuticsUT - Salt Lake City
1 programXeltis Vascular Patch, Model COR-VP-001N/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
XeltisXeltis Pulmonary Valved Conduit
Q TherapeuticsXeltis Vascular Patch, Model COR-VP-001
XeltisVascular Graft, Model COR-VG-001
Clinical Trials (3)
Xeltis Pulmonary Valved Conduit Safety and Performance Study
Start: Sep 2020Est. completion: Oct 2026
N/AWithdrawn
Safety and Performance of a Vascular Patch in Pediatric Patients Undergoing Bidirectional Cava-pulmonary Anastomosis
Start: Jun 2014Est. completion: Sep 2020
N/ACompleted
Safety and Performance of the COR-VG-001 Conduit in Pediatric Patients for Extracardiac Total Cavopulmonary Connection
Start: Oct 2013Est. completion: Sep 2020
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space